The global migraine drugs market size reached US$ 4.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 5.4 Billion by 2028, exhibiting a growth rate (CAGR) of 4.5% during 2023-2028. More Info:- https://www.imarcgroup.com/migraine-drugs-market

1. Copyright © IMARC Service Pvt Ltd. All Rights Reserved
Global Migraine Drugs
Market Research and
Forecast Report 2023-2028
Author: Elena Anderson,
Marketing Manager |
IMARC Group
© 2019 IMARC All Rights Reserved

2. Report Description
About IMARC Group
The International Market Analysis Research and Consulting Group is a leading adviser on
management strategy and market research worldwide. We partner with clients in all sectors
and regions to identify their highest-value opportunities, address their most critical
challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological
developments for business leaders in pharmaceutical, industrial, and high technology
organizations. Market forecasts and industry analysis for biotechnology, advanced materials,
chemicals, food and beverage, travel and tourism, nanotechnology and novel processing
methods are at the top of the company’s expertise.
IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and
markets with close cooperation at all levels of the client organization. This ensures that our
clients achieve unmatchable competitive advantage, build more proficient organizations, and
secure lasting results.

3. Report Description
Report Description and Highlights
Global Migraine Drugs Market Research Report:
The latest report by IMARC, titled “Migraine Drugs Market: Global Industry Trends, Share, Size,
Growth, Opportunity and Forecast 2023-2028” the global migraine drugs market is expected to grow
at a CAGR of 4.5% during 2023-2028.
Migraine drugs refer to medications that are used to reduce the severity of migraines and prevent
future attacks. A migraine is a severe, neurological disease with a debilitating headache, characterized
by an intense throbbing or pulsing in one area of the head. It is accompanied by sensitivity to light,
sound and smell, visual disturbances such as auras, and nausea or vomiting. Migraine drugs do not
cure migraines; instead, they treat or relieve these symptoms. There are certain blood pressure
medications, as well as some antidepressants, anti-seizure drugs and herbals that are used to reduce
the frequency of migraines.
Request Free Sample Report: https://www.imarcgroup.com/migraine-drugs-market/requestsample

4. Report Description
Report Description and Highlights
Global Migraine Drugs Market Trends:
According to the Migraine Trust, migraine is the third most common disease globally, with more than 10% of people
getting affected by the condition worldwide. This represents the primary factor that has increased the demand for
migraine drugs across the globe. Apart from this, the rising healthcare expenditure and improving reimbursement
policies for migraine medications are also acting as growth-inducing factors. Besides this, healthcare providers have
made significant advancements in the diagnosis and treatment of migraine. A more advanced treatment modality
with mechanism-based therapies, including supraorbital transcutaneous stimulation (STS) and transcranial magnetic
stimulation, has been introduced as a preventive therapy for migraine. Additionally, there are many other drugs with
novel mechanisms of action or new therapeutic targets, which are in different development stages.
Looking forward, the market value is projected to reach a strong growth during the forecast period
(2023-2028).

5. Report Description
Report Description and Highlights
Market Summary:
Breakup by Treatment Type:
• Abortive Treatment
• Preventive Treatment
Breakup by Drug Type:
• Triptans
• Ergot Alkaloids
• NSAIDs
• Acetylcholine Inhibitors/ Neurotoxins
• Ditans
• CGRP mAbs
• Others
Breakup by Route of Administration:
• Oral
• Injectable
• Others

6. Report Description
Report Description and Highlights
Breakup by Distribution Channel:
• Hospital-Based Pharmacies
• Retail Pharmacies
• Others
Breakup by Region:
• North America
• United States
• Canada
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France

7. Report Description
Report Description and Highlights
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

8. Competitive Landscape with Key Players:
• Abbott Laboratories
• Allergan Plc (Abbvie Inc.)
• Amgen Inc.
• AstraZeneca Plc
• Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals)
• Eisai Co. Ltd.
• Eli Lilly and Company
• Endo International Plc
• GlaxoSmithKline Plc
• Johnson & Johnson
• Merck & Co. Novartis AG
• Pfizer Inc.
• Sanofi SA
• Teva Pharmaceutical Industries Limited
View Full Report with TOC & List of Figure: https://www.imarcgroup.com/migraine-drugs-market
Report Description
Report Description and Highlights

9. A partial List of our Clients
We are the trusted business partners to the
world's leading corporates, governments, and
institutions
Partial List of Clients

10. A partial List of our Clients
We are the trusted business partners to the
world's leading corporates, governments, and
institutions
Partial List of Clients

11. Report Description
Report Description and Highlights
© 2019 IMARC All Rights Reserved
This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of
International Market Analysis Research and Consulting (IMARC). No part of this publication may be
reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be
used in any form or by and means graphic electronic or mechanical, including photocopying, recording,
taping or by information storage or retrieval, or by any other form, without the express consent of
International Market Analysis Research and Consulting (IMARC).
Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been
based on information and sources believed to be accurate and reliable at the time of publishing.
International Market Analysis Research and Consulting makes no representation of warranty of any kind as to
the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any
loss or damage resulting from opinion, errors or inaccuracies if any found this publication.
IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market
Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of
their respective companies.

12. FOR MORE DETAILS
Visit us at :
Stay With Us:
TELEPHONE: +1-631-791-1145
E-MAIL: sales@imarcgroup.com
https://www.imarcgroup.com
Contact Us